Have you been diagnosed with Nontuberculous Mycobacteria Lung Infection?
Learn about the Beyond Air pilot study, investigating the use of nitric oxide to treat Nontuberculous Mycobacteria (NTM). Nitric oxide is produced naturally by the body’s immune system to fight infection. Preliminary studies have indicated that nitric oxide possesses anti-microbial activity that may combat harmful pathogens.
Principal Investigator, Professor Rachel Thomson launched the study with the GMRF Clinical Trials Unit.
“It’s fabulous to be part of new options for patients,” Professor Thomson says.
“10 years ago, all people had available was a prolonged course of three
antibiotics. And if it didn’t work, you had no other options, and for a long time
there was nothing new on the horizon. Patients are looking for non-antibiotic
options for NTM and this system may provide a better quality of life,”
Professor Thomson says.
Study Objective
The Beyond Air trial, a proof of concept study, aims to assess the safety of high dose intermittent nitric oxide for treatment of NTM infection. The study offers participants a potential solution to help mitigate the symptoms of NTM infections.
Who is this study for?
To participate in this study you must:
- Be 18 years or older
- Have been diagnosed with refractory NTM
- Have been treated, for at least 6 months, with an NTM guideline-based treatment regimen within the last year
- Other eligibility criteria apply and will be assessed after contacting GMRF
What’s Involved?
If you are eligible for the study and agree to participate:
- You will first need to attend a screening visit at Greenslopes Private Hospital
- After, you will need to stay in the hospital for 5-6 days
- The rest of the treatment will take 12 weeks and is completed at home
Including the follow-up period, the process will take up to 6 months.
Contact gmrf@ramsayhealth.com.au or call 3394 7284 for more information.
We care about your data, view our Privacy Policy.